19.59
price down icon2.49%   -0.50
 
loading
전일 마감가:
$20.09
열려 있는:
$20.12
하루 거래량:
2.93M
Relative Volume:
1.23
시가총액:
$2.46B
수익:
$715.22M
순이익/손실:
$-250.10M
주가수익비율:
-9.6502
EPS:
-2.03
순현금흐름:
$-205.58M
1주 성능:
+0.62%
1개월 성능:
+6.53%
6개월 성능:
-34.70%
1년 성능:
-49.61%
1일 변동 폭
Value
$19.33
$20.30
1주일 범위
Value
$19.09
$20.32
52주 변동 폭
Value
$16.10
$41.94

아펠리스 Stock (APLS) Company Profile

Name
명칭
Apellis Pharmaceuticals Inc
Name
전화
617-977-5700
Name
주소
100 FIFTH AVENUE, WALTHAM, KY
Name
직원
710
Name
트위터
@ApellisPharma
Name
다음 수익 날짜
2024-12-05
Name
최신 SEC 제출 서류
Name
APLS's Discussions on Twitter

APLS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
APLS
Apellis Pharmaceuticals Inc
19.59 2.52B 715.22M -250.10M -205.58M -2.03
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

아펠리스 Stock (APLS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-09 다운그레이드 BofA Securities Buy → Neutral
2025-05-09 다운그레이드 Raymond James Strong Buy → Outperform
2025-04-29 개시 Cantor Fitzgerald Overweight
2024-12-17 다운그레이드 Goldman Buy → Neutral
2024-11-21 개시 Morgan Stanley Equal-Weight
2024-10-25 개시 RBC Capital Mkts Sector Perform
2024-10-16 개시 Scotiabank Sector Outperform
2024-10-16 개시 William Blair Outperform
2024-05-31 개시 Piper Sandler Neutral
2024-02-05 업그레이드 Jefferies Hold → Buy
2023-12-14 다운그레이드 Wells Fargo Overweight → Equal Weight
2023-11-09 개시 Goldman Buy
2023-11-02 개시 Mizuho Neutral
2023-10-06 업그레이드 JP Morgan Neutral → Overweight
2023-09-15 업그레이드 Wells Fargo Equal Weight → Overweight
2023-08-29 재확인 Citigroup Buy
2023-08-03 다운그레이드 JP Morgan Overweight → Neutral
2023-08-01 다운그레이드 BofA Securities Buy → Neutral
2023-01-03 다운그레이드 Wells Fargo Overweight → Equal Weight
2022-11-10 다운그레이드 Jefferies Buy → Hold
2022-07-19 개시 H.C. Wainwright Buy
2022-06-17 재개 Stifel Buy
2022-04-14 다운그레이드 ROTH Capital Neutral → Sell
2021-12-08 개시 Wells Fargo Overweight
2021-11-29 다운그레이드 ROTH Capital Buy → Neutral
2021-09-10 재확인 BMO Capital Markets Outperform
2021-09-10 재확인 Credit Suisse Neutral
2021-09-10 재확인 Needham Buy
2021-09-10 재확인 Oppenheimer Outperform
2021-09-10 다운그레이드 Wedbush Outperform → Neutral
2021-08-19 개시 Jefferies Buy
2021-08-19 업그레이드 Wedbush Neutral → Outperform
2021-05-21 개시 UBS Buy
2021-04-16 개시 Goldman Buy
2020-11-19 개시 Needham Buy
2020-09-01 개시 Stifel Buy
2020-07-20 개시 ROTH Capital Buy
2020-06-17 개시 BTIG Research Neutral
2020-04-01 개시 Raymond James Strong Buy
2020-03-31 개시 BMO Capital Markets Outperform
2020-03-11 업그레이드 Wedbush Underperform → Neutral
2020-01-07 개시 SVB Leerink Mkt Perform
2019-12-19 개시 BofA/Merrill Buy
2019-11-22 개시 Wedbush Underperform
2019-11-05 개시 Credit Suisse Neutral
2019-08-01 재확인 Cantor Fitzgerald Overweight
2019-07-12 업그레이드 JP Morgan Neutral → Overweight
2019-03-29 개시 Robert W. Baird Outperform
2019-01-23 다운그레이드 JP Morgan Overweight → Neutral
2018-07-30 업그레이드 B. Riley FBR Neutral → Buy
2018-05-24 개시 Cantor Fitzgerald Overweight
2018-04-12 다운그레이드 B. Riley FBR, Inc. Buy → Neutral
2018-02-08 개시 B. Riley FBR, Inc. Buy
모두보기

아펠리스 주식(APLS)의 최신 뉴스

pulisher
Jul 25, 2025

Is Apellis Pharmaceuticals Inc. a good long term investmentOver 200% growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Apellis Pharmaceuticals Inc. stockSky-high return potential - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025 - GuruFocus

Jul 24, 2025
pulisher
Jul 24, 2025

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - The Manila Times

Jul 24, 2025
pulisher
Jul 24, 2025

Fierce Biotech Layoff Tracker 2025: Rocket ejects 30% of staffers; Flagship's Tessera and Generate Bio trim teams - Fierce Biotech

Jul 24, 2025
pulisher
Jul 23, 2025

Complement 3 Glomerulopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma - Barchart.com

Jul 23, 2025
pulisher
Jul 23, 2025

Apellis Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding trading profits - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Apellis Pharmaceuticals Inc. stock priceExceptional market performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Intermediate Age-Related Macular Degeneration Market Research 2025-2035 Featuring Novartis, Allegro Ophthalmics, and Apellis PharmaceuticalsResearchAndMarkets.com - FinancialContent

Jul 21, 2025
pulisher
Jul 18, 2025

Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛

Jul 18, 2025
pulisher
Jul 18, 2025

Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga

Jul 18, 2025
pulisher
Jul 16, 2025

APLS Stock Update: B of A Securities Raises Price Target | APLS - GuruFocus

Jul 16, 2025
pulisher
Jul 16, 2025

Apellis price target raised to $24 from $23 at BofA - TipRanks

Jul 16, 2025
pulisher
Jul 15, 2025

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - The Manila Times

Jul 15, 2025
pulisher
Jul 15, 2025

Apellis Reveals 48-Month SYFOVRE Data: 5 Key Studies Show Promise for Geographic Atrophy Treatment - Stock Titan

Jul 15, 2025
pulisher
Jul 14, 2025

H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada

Jul 14, 2025
pulisher
Jul 14, 2025

How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 11, 2025

Apellis Pharmaceuticals (APLS) Receives a Buy from Cantor Fitzgerald - The Globe and Mail

Jul 11, 2025
pulisher
Jul 11, 2025

Apellis stock holds Outperform rating at William Blair amid Izervay competition - Investing.com Canada

Jul 11, 2025
pulisher
Jul 10, 2025

Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Cantor Fitzgerald reiterates Apellis stock Overweight rating with $39 target By Investing.com - Investing.com Canada

Jul 10, 2025
pulisher
Jul 10, 2025

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail

Jul 10, 2025
pulisher
Jul 08, 2025

16 Most Promising Stocks According to Wall Street Analysts - Insider Monkey

Jul 08, 2025
pulisher
Jul 07, 2025

Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

Morgan Stanley raised the Target Price of Apellis Pharmaceuticals (APLS.US) to $26 and maintained a "Hold" rating. - 富途牛牛

Jul 07, 2025
pulisher
Jul 06, 2025

Apellis stock surges after Sobi $300 million royalty deal - MSN

Jul 06, 2025
pulisher
Jul 05, 2025

Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing - MSN

Jul 05, 2025
pulisher
Jul 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

WilmerHale Advises Apellis Pharmaceuticals in Purchase Agreement with Sobi - WilmerHale

Jul 03, 2025
pulisher
Jul 03, 2025

(APLS) Trading Advice - news.stocktradersdaily.com

Jul 03, 2025
pulisher
Jul 03, 2025

Apellis signs royalty purchase deal with Sobi for Aspaveli - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - MSN

Jul 03, 2025
pulisher
Jul 03, 2025

Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX) - The Globe and Mail

Jul 03, 2025
pulisher
Jul 02, 2025

What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Nasdaq

Jul 02, 2025

아펠리스 (APLS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
자본화:     |  볼륨(24시간):